Epidermal Growth Factor Receptor Inhibitor–Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management
Author:
Affiliation:
1. a Massachusetts General Hospital, Boston, Massachusetts, USA
2. b MD Anderson Cancer Center, Houston, Texas, USA
3. c University of Pennsylvania, Philadelphia, Pennsylvania, USA
4. d Northwestern University, Chicago, Illinois, USA
Abstract
Publisher
Oxford University Press (OUP)
Subject
Cancer Research,Oncology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.12-5-610
Reference58 articles.
1. Issues and progress with protein kinase inhibitors for cancer treatment;Dancey;Nat Rev Drug Discov,2003
2. ERBB receptors and cancer: The complexity of targeted inhibitors;Hynes;Nat Rev Cancer,2005
Cited by 297 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. An Analysis of Risk Factors for the Development of Acneiform Eruptions in Patients on Monoclonal Antibody Epidermal Growth Factor Receptor Inhibitors;Journal of Cutaneous Medicine and Surgery;2023-11
2. Engineering of Amphiphilic Erlotinib Analogue as Novel Nanomedicine for Non-Small Cell Lung Cancer Therapy;International Journal of Nanomedicine;2023-11
3. Dermatological Side Effects of Cancer Treatment: Psychosocial Implications—A Systematic Review of the Literature;Healthcare;2023-09-25
4. ACTH/cAMP-Mediated Skin Pigmentation Caused by 5-Fluorouracil Administration;Biological and Pharmaceutical Bulletin;2023-07-01
5. Dermatological adverse drug reactions to tyrosine kinase inhibitors: a narrative review;Clinical and Experimental Dermatology;2023-02-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3